Nutra Pharma Stock Forecast, Price & News

0.00 (0.00 %)
(As of 08/3/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume2.76 million shs
Average Volume22.72 million shs
Market Capitalization$26.51 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive NPHC News and Ratings via Email

Sign-up to receive the latest news and ratings for Nutra Pharma and its competitors with MarketBeat's FREE daily newsletter.

Nutra Pharma logo

About Nutra Pharma

Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and homeopathic and ethical drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases primarily in the United States. The company offers Nyloxin and Nyloxin Extra Strength products, which are used as an oral spray for treating back pain, neck pain, headaches, joint pain, migraines, and neuralgia, as well as a topical gel for treating joint pain, neck pain, arthritis pain, and pain associated with repetitive stress; Pet Pain-Away, an over-the-counter pain reliever to treat pain in cats and dogs; Luxury Feet, an over-the-counter pain reliever to treat foot pain from high heels and stilettos; Nyloxin Military Strength for treating pain to the United States Military and Veteran's Administration; and Equine Pain-Away, a topical therapy for chronic pain for use in equine industry. It is also involved in developing RPI-78M to treat neurological diseases and autoimmune diseases, including multiple sclerosis, adrenomyeloneuropathy, amyotrophic lateral sclerosis, rheumatoid arthritis, and myasthenia gravis; RPI-MN to treat viral diseases, including human immunodeficiency virus/AIDS and herpes, as well as for general anti-viral applications; RPI-78 for pain and arthritis; and RPI-70 for pain. The company was incorporated in 2000 and is based in Plantation, Florida.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.32 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Nutra Pharma (OTCMKTS:NPHC) Frequently Asked Questions

What stocks does MarketBeat like better than Nutra Pharma?

Wall Street analysts have given Nutra Pharma a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Nutra Pharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Nutra Pharma's earnings last quarter?

Nutra Pharma Corp. (OTCMKTS:NPHC) issued its quarterly earnings results on Friday, August, 17th. The company reported $0.00 EPS for the quarter. The business earned $0.03 million during the quarter.
View Nutra Pharma's earnings history

How has Nutra Pharma's stock been impacted by Coronavirus?

Nutra Pharma's stock was trading at $0.0008 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, NPHC stock has increased by 393.8% and is now trading at $0.0040.
View which stocks have been most impacted by COVID-19

Who are Nutra Pharma's key executives?

Nutra Pharma's management team includes the following people:
  • Mr. Erik J. Deitsch, Chairman, CEO, Pres & CFO (Age 53, Pay $130k)
  • Dr. Dale VanderPutten, Chief Scientific Officer (Age 62, Pay $144k)
  • Mr. Neil Roth, Pres of Designer Diagnostics, Inc
  • Ms. Nina Goldstein, Sec. (Age 61)

Who are some of Nutra Pharma's key competitors?

What other stocks do shareholders of Nutra Pharma own?

What is Nutra Pharma's stock symbol?

Nutra Pharma trades on the OTCMKTS under the ticker symbol "NPHC."

How do I buy shares of Nutra Pharma?

Shares of NPHC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nutra Pharma's stock price today?

One share of NPHC stock can currently be purchased for approximately $0.00.

How much money does Nutra Pharma make?

Nutra Pharma has a market capitalization of $26.51 million and generates $100,000.00 in revenue each year.

How many employees does Nutra Pharma have?

Nutra Pharma employs 4 workers across the globe.

What is Nutra Pharma's official website?

The official website for Nutra Pharma is www.nutrapharma.com.

Where are Nutra Pharma's headquarters?

Nutra Pharma is headquartered at 12538 WEST ATLANTIC BLVD., CORAL SPRINGS FL, 33071.

How can I contact Nutra Pharma?

Nutra Pharma's mailing address is 12538 WEST ATLANTIC BLVD., CORAL SPRINGS FL, 33071. The company can be reached via phone at 954-509-0911 or via email at [email protected]

This page was last updated on 8/4/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.